ABSTRACT
Clinical psychiatric experience demonstrates a wide range of variation in behavioral responses to physiological therapies. Present techniques of evaluating therapies by global improvement scores, imprecise diagnostic classification, and target symptoms abstracted from their context were felt to be methodologically inadequate. Following our experience in describing the behavioral reaction patterns to convulsive (4) and phenothiazine(6) therapies, a similar analysis of the data derived from imipramine (Tofrānil) therapy was undertaken.
